Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication

被引：9

作者：

Skerlj, Renato ^{[1
]}

Bridger, Gary ^{[2
]}

Zhou, Yuanxi ^{[2
]}

Bourque, Elyse ^{[1
]}

McEachern, Ernest ^{[2
]}

Danthi, Sanjay ^{[1
]}

Langille, Jonathan ^{[2
]}

Harwig, Curtis ^{[2
]}

Veale, Duane ^{[2
]}

Carpenter, Bryon ^{[2
]}

Ba, Tuya ^{[2
]}

Bey, Michael ^{[2
]}

Baird, Ian ^{[2
]}

Wilson, Trevor ^{[2
]}

Metz, Markus ^{[1
]}

MacFarland, Ron ^{[2
]}

Mosi, Renee ^{[2
]}

Bodart, Veronique ^{[2
]}

Wong, Rebecca ^{[2
]}

Fricker, Simon ^{[1
]}

Huskens, Dana ^{[3
]}

Schols, Dominique ^{[3
]}

机构：

[1] Genzyme Corp, Waltham, MA 02451 USA

[2] Anormed Inc, Langley, BC V2Y 1N5, Canada

[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 03期

基金：

英国医学研究理事会;

关键词：

HIV-1; hERG; CCR5; chemokine receptor; LONG-QT SYNDROME; MARAVIROC; GO;

D O I：

10.1021/ml2002604

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing lipophilicity was the main design criteria used to identify compounds that did not inhibit the hERG channel, but subtle structural modifications were also important. Interestingly, within this series, compounds with low hERG inhibition prolonged the action potential duration (APD) in dog Purkinje fibers, suggesting a mixed effect on cardiac ion channels.

引用

页码：216 / 221

页数：6

共 50 条

[31] Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
Henrich, Timothy J.
Lewine, Nicolas R. P.
Lee, Sun-Hee
Rao, Suhas S. P.
Berro, Reem
Gulick, Roy M.
Moore, John P.
Tsibris, Athe M. N.
Kuritzkes, Daniel R.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 1931 - 1935
[32] CCR5 Utilization of Transmitted and Early Founder HIV-1 Envelopes and the Sensitivity to Small CCR5 Inhibitors
Hu, Q.
Keele, B.
Ping, L.
Grayson, T.
Sun, C.
Hahn, B.
Shattock, R.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 6 - 6
[33] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
Henrich, T. J.
Lewine, N.
Lee, S-H
Rao, S.
Berro, R.
Greaves, W.
Gulick, R.
Tsibris, A.
Moore, J.
Kuritzkes, D.
ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
[34] Discovery of potent, selective and orally active CCR5 antagonists for the potential treatment of HIV infection.
Tagat, J
McCombie, S
Nazareno, D
Steensma, R
Labroli, M
Baroudy, B
Strizki, J
Cox, K
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U175 - U175
[35] Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors
Muraglia, Ester
Kinzel, Olaf
Gardelli, Cristina
Crescenzi, Benedetta
Donghi, Monica
Ferrara, Marco
Nizi, Emanuela
Orvieto, Federica
Pescatore, Giovanna
Laufer, Ralph
Gonzalez-Paz, Odalys
Di Marco, Annalise
Fiore, Fabrizio
Monteagudo, Edith
Fonsi, Massimiliano
Felock, Peter J.
Rowley, Michael
Summa, Vincenzo
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) : 861 - 874
[36] Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist
Takashima, K
Miyake, H
Kanzaki, N
Tagawa, Y
Wang, X
Sugihara, Y
Iizawa, Y
Baba, M
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3474 - 3482
[37] Interaction of small molecule inhibitors of HIV-1 entry with CCR5
Seibert, Christoph
Ying, Weiwen
Gavrilov, Svetlana
Tsamis, Fotini
Kuhmann, Shawn E.
Palani, Anandan
Tagat, Jayaram R.
Clader, John W.
McCombie, Stuart W.
Baroudy, Bahige M.
Smith, Steven O.
Dragic, Tatjana
Moore, John P.
Sakmar, Thomas P.
VIROLOGY, 2006, 349 (01) : 41 - 54
[38] Preferential recognition of monomeric CCR5 expressed in cultured cells by the HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1
Nakano, Yusuke
Monde, Kazuaki
Terasawa, Hiromi
Yuan, Yuzhe
Yusa, Keisuke
Harada, Shinji
Maeda, Yosuke
VIROLOGY, 2014, 452 : 117 - 124
[39] Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
Benkirane, M
Jin, DY
Chun, RF
Koup, RA
Jeang, KT
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) : 30603 - 30606
[40] CCR5 antagonists and HIV-1 infection: Bases and consequences of this therapeutic approach
Psomas, K. C.
Corbeau, P.
Reynes, J.
ANTIBIOTIQUES, 2010, 12 (01): : 27 - 41

← 1 2 3 4 5 →